Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index; 7 of the 73 sources its claims cite were checked for support.
Abstract
BACKGROUND: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting, particularly in the intensive care unit (ICU). OBJECTIVES AND METHODS: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and a European expert panel discussion. RESULTS AND CONCLUSIONS: Candida albicans remains the most frequently isolated fungal species followed by C. glabrata. The diagnosis of invasive candidiasis involves both clinical and laboratory parameters, but neither of these are specific. One of the main features in diagnosis is the evaluation of risk factor for infection which will identify patients in need of pre-emptive or empiric treatment. Clinical scores were built from those risk factors. Among laboratory diagnosis, a positive blood culture from a normally sterile site provides positive evidence. Surrogate markers have also been proposed like 1,3 beta-D: glucan level, mannans, or PCR testing. Invasive candidiasis and candidemia is a growing concern in the ICU, apart from cases with positive blood cultures or fluid/tissue biopsy, diagnosis is neither sensitive nor specific. The diagnosis remains difficult and is usually based on the evaluation of risk factors.
Overview
CoChat Summary
TL;DR
This narrative review summarizes the epidemiology and diagnosis of invasive candidiasis and candidemia in adult non-neutropenic ICU patients, emphasizing high attributable mortality and persistent diagnostic difficulty. It reports that Candida spp. are common ICU bloodstream pathogens, C. albicans remains predominant although non-albicans species are increasingly reported, and diagnosis relies on risk factors, colonization indices, cultures, and non-culture markers with imperfect accuracy.
Key findings
- Candida spp. account for 6–11% of positive nosocomial bloodstream infections; in a US surveillance study, 4.6 bloodstream infections per 10,000 admissions and 9% of all bloodstream infections. ICU candidemia was 10.1% of bloodstream infections versus 7.9% on general wards, and one study reported 15.8/10,000 patient-days in ICUs versus 0.15/10,000 on medical wards and 0.69/10,000 on surgical wards.
- Attributable mortality of candidiasis was estimated at 49% in 108 matched pairs, with crude mortality 61% in case patients versus 12% in controls; a systematic review of seven matched cohort and case-control studies reported attributable mortality ranging from 5 to 71%. Invasive candidiasis and candidemia were associated with increased ICU and hospital stay of 12.7 and 15.5 days, respectively.
- C. albicans remained the main pathogen overall, but non-albicans species were increasingly reported. In an Italian ICU study of 182 candidemia episodes, 40% were C. albicans, 23% C. parapsilosis, 15% C. glabrata, 9% C. tropicalis, and 13% other species; in a Canadian 1-day point-prevalence study of 409 isolates, C. albicans accounted for 72% and C. glabrata 16%, with only 4% resistant to fluconazole and/or itraconazole.
- Diagnosis is challenging: clinical manifestations are non-specific, blood cultures are often positive late, and about 50% of blood culture samples may be inadequate (<20 mL). Reported test performance included beta-D-glucan sensitivity 69.9% and specificity 87.1%; combined mannan/antimannan sensitivity 80% and specificity 93%; and a PCR assay sensitivity 90.9% and specificity 100%. The Pittet colonization index threshold of 0.5 and a corrected index were associated with 100% sensitivity and specificity in a 29-patient study; the Leon Candida score cut-off of 2.5 had sensitivity 81% and specificity 74%.
Methods
- Narrative review of the international literature on management of invasive candidiasis and candidemia in adult non-neutropenic ICU patients, focused here on epidemiology and diagnosis.
- No primary patient cohort, systematic search strategy, or meta-analysis is described; the paper synthesizes findings from cited epidemiologic, risk-factor, prediction-rule, colonization-index, and laboratory-diagnostic studies.
- Main analysis is descriptive, covering incidence and mortality, Candida species distribution, risk factors, clinical prediction rules, colonization indices, and laboratory markers including beta-D-glucan, mannan/antimannan, germ tube antibody, and PCR.
Limitations
- The paper states that diagnosis is neither sensitive nor specific apart from positive blood cultures or fluid/tissue biopsy, and that there is a clear need for more specific diagnostic markers. It also states that uncertainty exists around the relative mortality of different Candida species, requiring well-controlled studies, and that the influence of azole prophylaxis on Candida epidemiology has not been clearly elucidated.
- The paper notes limitations of specific cited evidence, including that one prediction study involved only 19 patients with candidemia, that the Pittet colonization-index study evaluated 29 patients, that PCR results need further evaluation, and that beta-D-glucan requires validation in the appropriate ICU setting before routine use.
- Evident from the text: as a narrative review without a described systematic search or formal quality assessment, the reported incidence, species distribution, and mortality estimates vary widely across heterogeneous, often small, retrospective, or single-center studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 56 Not checked · 9 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A larger study conducted over a 5-year period in Italy recorded 182 episodes of ICU candidemia, with an average incidence of 2.22 episodes/10,000 patient-days/ year [22].”
What the sources say
- Supportedcites [22] Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21 source
The Abstract Methods (p. 1) and Background/Methods sections establish a five-year (1999–2003) retrospective study in the ICU of San Martino University Hospital, Genoa, Italy. The Results (p. 1) and Table 2 state 182 episodes of candidaemia with an average incidence of 2.22 episodes/10 000 patient-days/year (range 1.25–3.06), matching every element of the claim. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results of this study reflected a shift toward an increased rate of infection with non-albicans Candida species.”
What the sources say
- Supportedcites [22] Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21 source
The Background identifies the study as a retrospective analysis of bloodstream infections in an ICU in Genova, Italy. The Results report that the proportion of non-albicans isolates increased during 1999–2003, and the Discussion explicitly describes a shift toward non-albicans Candida species in the ICU population. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The authors developed a corrected index (product of the CI times the ratio of the number of dbs showing heavy growth to the total of dbs growing Candida spp.) which was associated with a 100% sensitivity and specificity.”
What the sources say
- Supportedcites [46] Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751-758 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“and candidemia occurred more frequently in non-neutropenic patients than in patients with neutropenia [1,7].”
What the sources say
- Not checked yetcites [1] Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317 source
- Not checked yetcites [7] Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY (2008) Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 34:292-299 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Comparing fluconazole-susceptible with resistant strains in 161 patients, Kovacicova et al. [19] found a significantly higher attributable mortality in patients infected with a fluconazole-resistant strain.”
What the sources say
- Not checked yetcites [19] Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, Hanzen J, Milosovic P, Lamosova M, Macekova L, Szovenyiova Z, Purgelova A, Obertik T, Bille J, Krcmery V (2000) Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother 6:216- 221 source
plainstates an associationn = 161- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
15 more claims
Create a free account to see all 71 claims and to verify the 66 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These possible treatment delays likely occurred because of the non-specific clinical presentation of candidemia, low sensitivity of blood cultures for candidemia detection, and the time needed to detect Candida in blood cultures [15, 27].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [27]
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 4×
“varies depending on the population surveyed [1, 2].”
BackgroundInfluentialEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 4×
“varies depending on the population surveyed [1, 2].”
BackgroundInfluentialMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 1×
“specimens require invasive procedures [29, 30, 46].”
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 1×
“Attributable mortality of candidiasis was evaluated retrospectively between 1997 and 2001 in 108 matched pairs [12], the crude mortality among case patients was 61% compared with 12% in”
ResultHospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798 · cited 2×
“specimens require invasive procedures [29, 30, 46].”
BackgroundOstrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669 · cited 1×
“1%, respectively [47], as there are a high number of false positive results.”
BackgroundBlumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661 · cited 3×
“Table 1 Commonly recognized risk factors for invasive Candida infection [2, 34, 35]”
BackgroundLeón, C., Ruiz-Santana, S., Saavedra, P., Almirante, B., Nolla-Salas, J., Álvarez-Lerma, F., Garnacho-Montero, J., & León, M. Á. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202208.37364.7d · Cited by 659 · cited 3×
“[28] described a clinical score based on four parameters derived from a logit model: surgery, multifocal colonization, total parenteral nutrition, and severe sepsis.”
BackgroundMethodViscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“[18] also suggested that C.”
Cited by
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
“ICU-acquired candidemia patients characteristically have several underlying medical and surgical risk factors, and are frequently exposed to high-risk medications [5].”
BackgroundInvasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
Influentialde Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
“Candidemia is such an important infection that in 10–40% of cases it is associated with sepsis or septic shock while Candida species as main agent of sepsis or septic shock are responsible for no more than 5% of the total number of cases (Guery et al., 2009).”
BackgroundFalagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346
A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality.
Bassetti, M., Righi, E., Ansaldi, F., Merelli, M., Cecilia, T., De Pascale, G., Diaz-Martin, A., Luzzati, R., Rosin, C., Lagunes, L., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3310-z · Cited by 284
“from 23 to 38 %, respectively [9–14].”
BackgroundBassetti, M., Giacobbe, D. R., Vena, A., Trucchi, C., Ansaldi, F., Antonelli, M., Adamkova, V., Alicino, C., Almyroudi, M.-P., Atchade, E., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2497-3 · Cited by 270
Self-citationHöfs, S., Mogavero, S., & Hube, B. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5514-0 · Cited by 238
“However, systemic infection in particular may also arise by introducing C. albicans by external routes, e.g. via central venous catheters (Guery et al., 2009; Ramage et al., 2009; Gow and Hube, 2012).”
BackgroundIntensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
Self-citationInvasive Mycoses: Diagnostic Challenges
Ostrosky-Zeichner, L. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.008 · Cited by 176
Invasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F., Flevari, A., Armaganidis, A., & Dimopoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 175
“Moreover in deep-seated candidiasis or in patients under fluconazole prophylaxis, BCs are often negative [36,37].”
BackgroundEggimann, P., & Pittet, D. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3355-z · Cited by 140
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 129
Treatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 137
Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-015-0103-7 · Cited by 102
“Major risk factors for IC are well known [3, 4, 7, 28]; however, they are so common in ICU patients than other tools are needed.”
BackgroundLeroy, G., Lambiotte, F., Thévenin, D., Lemaire, C., Parmentier, E., Devos, P., & Leroy, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-50 · Cited by 92
SCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Tadec, L., Talarmin, J., Gastinne, T., Bretonnière, C., Miegeville, M., Le Pape, P., & Morio, F. (2016) · Mycoses · doi:10.1111/myc.12470 · Cited by 80
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
“glabrata versus Candida albicans as a means of providing appropriate early therapy (Chow et al., 2008; Guery et al., 2009; Hedderwick et al., 1998; Lee et al., 2009; Magill et al., 2006; Parkins et al., 2007; Shorr et al., 2007).”
BackgroundOpportunistic pathogen Candida albicans elicits a temporal response in primary human mast cells
Lopes, J. P., Stylianou, M., Nilsson, G., & Urban, C. F. (2015) · Scientific Reports · doi:10.1038/srep12287 · Cited by 75
Preventing invasive candida infections. Where could we do better?
Eggimann, P., Que, Y.-A., Revelly, J.-P., & Pagani, J.-L. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.11.006 · Cited by 74
European expert opinion on the management of invasive candidiasis in adults
Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Billé, J., Calandra, T., Cuenca‐Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03615.x · Cited by 78
“Which antifungal agent should be used to treat an azole-naı̈ve, non-neutropenic, adult ICU patient with candidaemia? Background: Medical and surgical ICUs have seen a substantial increase in the incidence of invasive candidiasis in recent years [4].”
BackgroundSelf-citationAcylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids
Lazzarini, C., Haranahalli, K., Rieger, R. A., Ananthula, H. K., Desai, P. B., Ashbaugh, A., Linke, M. J., Cushion, M. T., Ruzsicska, B. P., Haley, J. D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00156-18 · Cited by 73
“As a result, disseminated candidiasis is the 4th most common hospital-acquired sepsis, with (cid:2) 120,000 deaths/year (10–12).”
Evaluation of species distribution and risk factors of candidemia: A multicenter case-control study
Yapar, N., Pullukcu, H., Avkan-Oguz, V., Sayin-Kutlu, S., Ertugrul, B., Sacar, S., Cetin, B., & Kaya, O. (2011) · Medical Mycology · doi:10.3109/13693786.2010.501344 · Cited by 69
Efficacy of antifungal drugs in the treatment of oral candidiasis: A Bayesian network meta-analysis
Fang, J., Huang, B., & Ding, Z. (2020) · Journal of Prosthetic Dentistry · doi:10.1016/j.prosdent.2019.12.025 · Cited by 81
Novel strategies to fightCandidaspecies infection
Rodrigues, M. E., Silva, S. M., Azeredo, J., & Henriques, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.974500 · Cited by 80
“It is associated with a high global mortality rate, ranging from 36% to 63% in different patient groups (Gudlaugsson et al., 2003; Guery et al., 2009; Kullberg et al., 2011; Marchetti et al., 2004; Pappas et al., 2003; Tortorano et al., 2004; Van de Veerdonk et al., 2010; Wisplinghoff et al., 2004;…”
BackgroundSouza, L. C. D., da Motta, V. B. R., de CARVALHO, A. V. D. S. Z., Corrêa, R. D. G. C. F., Libério, S. A., & Lopes, F. F. (2017) · Brazilian Oral Research · doi:10.1590/1807-3107bor-2017.vol31.0038 · Cited by 76
Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis
Liu, P., Ruhnke, M., Meersseman, W., Paiva, J. A., Kantecki, M., & Damle, B. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02139-12 · Cited by 66
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Failure of Empirical Systemic Antifungal Therapy in Mechanically Ventilated Critically Ill Patients
Bailly, S., Bouadma, L., Azoulay, É., Garrouste-Orgeas, M., Adrie, C., Souweine, B., Schwebel, C., Maubon, D., Hamidfar-Roy, R., Darmon, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201409-1701oc · Cited by 64
Self-citationSevere Candida spp. infections: new insights into natural immunity
van der Meer, J. W. M., van de Veerdonk, F. L., Joosten, L. A. B., Kullberg, B. J., & Netea, M. G. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.013 · Cited by 70
Self-citationCurrent diagnostic approaches to invasive candidiasis in critical care settings
Pemán, J., & Zaragoza, R. (2010) · Mycoses · doi:10.1111/j.1439-0507.2009.01732.x · Cited by 69
Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit
Bassetti, M., Mikulska, M., & Viscoli, C. (2010) · Critical Care · doi:10.1186/cc9239 · Cited by 57
Ruhnke, M., Paiva, J. A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03784.x · Cited by 58
“The observed species distribution matched what would be expected from a pan-European study [28–31] and MICs were similar to those reported previously [13].”
Self-citationSmeekens, S. P., van de Veerdonk, F. L., Joosten, L. A. B., Jacobs, L., Jansen, T., Williams, D. L., van der Meer, J. W. M., Kullberg, B. J., & Netea, M. G. (2011) · European Journal of Immunology · doi:10.1002/eji.201141418 · Cited by 70
Self-citationWang, H., Liu, N., Yin, M., Han, H., Yue, J., Zhang, F., Shan, T., Guo, H., & Wu, D. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0609-x · Cited by 52
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Soulountsi, V., Schizodimos, T., & Kotoulas, S. (2021) · Infection · doi:10.1007/s15010-021-01640-7 · Cited by 59
Dąbrowski, M., Sharma, P. S., Iskierko, Z., Noworyta, K., Cieplak, M., Lisowski, W., Oborska, S., Kuhn, A., & Kutner, W. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.12.088 · Cited by 52
Ceresa, C., Rinaldi, M., Chiono, V., Carmagnola, I., Allegrone, G., & Fracchia, L. (2016) · Antonie van Leeuwenhoek · doi:10.1007/s10482-016-0736-z · Cited by 57
“…Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy global mortality rate, ranging from 36 to 63 % in different patient groups (Guery et al. 2009; van De Veerdonk et al. 2010) and represents a significant problem in terms of patient management and healthcare costs in the…”
BackgroundMethodDiagnosis of bacteraemia and growth times
Ruiz‐Giardín, J. M., Martin-Diaz, R. M., Aroca, J. J., García-Arata, I., Martín, J. S., & Buitrago, M. S.-S. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.10.008 · Cited by 51
Glöckner, A. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-167 · Cited by 53
“This distribution reflects the predisposing factors identified by several authors [12], including neutropenia, cancer chemotherapy, colonization with Candida spp.”
BackgroundCandida albicans and non-Candida albicans fungemia in an institutional hospital during a decade
Parmeland, L., Gazon, M., Guerin, C., Argaud, L., Lehot, J.-J., Bastien, O., Allaouchiche, B., Michallet, M., Picot, S., Bienvenu, A.-L., et al. (2013) · Medical Mycology · doi:10.3109/13693786.2012.686673 · Cited by 45
Phytochemicals and Their Antifungal Potential against Pathogenic Yeasts
Monteiro, C. D. A., & dos Santos, J. R. A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87302 · Cited by 50
“Candidemia is such an important infection that in 10–40% of cases, it is associated with sepsis or septic shock [41].”
BackgroundTang, X., Hua, Y., Guan, Q., & Yuan, C. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2574-8 · Cited by 43
Vasileiou, E., Apsemidou, A., Vyzantiadis, T., & Tragiannidis, A. (2018) · Current Medical Mycology · doi:10.18502/cmm.4.3.173 · Cited by 41
Heimann, S. M., Cornely, O. A., Wisplinghoff, H., Kochanek, M., Stippel, D. L., Padosch, S. A., Langebartels, G., Reuter, H., Reiner, M., Vierzig, A., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2230-8 · Cited by 37
Candida Colonization and Candiduria in Critically Ill Patients in the Intensive Care Unit
Viale, P. (2009) · Drugs · doi:10.2165/11315640-000000000-00000 · Cited by 40
Invasive candidiasis: update on current pharmacotherapy options and future perspectives
Tragiannidis, A., Tsoulas, C., Kerl, K., & Groll, A. H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.805204 · Cited by 40
“Despite improvements in antifungal prevention and treatment that came with the discovery of newer azoles and echinocandins, the disease is associated with high mortality rates, ranging from 36 to 63% in different patient groups [1-4].”
BackgroundAlkanfari, I., Freeman, K. B., Roy, S., Jahan, T., Scott, R. W., & Ali, H. (2019) · Cells · doi:10.3390/cells8040311 · Cited by 32
Fungal infections in immunocompromised patients
Sganga, G. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02134.x · Cited by 34
Self-citationAntonelli, M. M., Azoulay, É., Bonten, M. J. M., Chastre, J. E., Citerio, G., Conti, G., Backer, D. D., Lemaire, F., Gerlach, H., Hedenstierna, G., et al. (2010) · Intensive Care Medicine · doi:10.1007/s00134-009-1742-7 · Cited by 31
“Interestingly, invasive candidiasis was the topic of a two-part review by Guery et al [18, 19].”
BackgroundSelf-citationInvasive Candida Infections in the ICU: Diagnosis and Therapy
Hankovszky, P., Társy, D., Öveges, N., & Molnár, Z. (2015) · The Journal of Critical Care Medicine · doi:10.1515/jccm-2015-0025 · Cited by 31
“Recent studies indicate it varies between 40-60% [10-12] and within certain conditions mortality can reach 100% [5].”
BackgroundFungal Infections in Immunosuppressed Patients
Puebla, L. E. J. (2012) · InTech eBooks · doi:10.5772/51512 · Cited by 42
Invasive candidiasis and candidaemia in neonates and children: update on current guidelines
Tragiannidis, A., Tsoulas, C., & Groll, A. H. (2014) · Mycoses · doi:10.1111/myc.12268 · Cited by 41
Immunotherapy: a potential adjunctive treatment for fungal infection
Kullberg, B. J., van de Veerdonk, F. L., & Netea, M. G. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000105 · Cited by 30
Self-citationCoping with Candida Infections
Evans, S. E. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200907-075al · Cited by 32
Intra-abdominal candidiasis: it’s still a long way to get unquestionable data
Montravers, P., Leroy, O., & Eckmann, C. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3894-y · Cited by 28
“with candidaemia, including conventional risk factors [4] and high morbidity and mortality rates [2, 3, 5].”
BackgroundRüping, M. J. G. T., Vehreschild, J. J., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Cornely, O. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01989.x · Cited by 24
Reboli, A. C., Rotstein, C., Kett, D. H., Maschio, M., Cartier, S., Chambers, R. B., & Tarallo, M. (2011) · PharmacoEconomics · doi:10.2165/11584810-000000000-00000 · Cited by 26
Self-citationShao, B., Ma, Y., Li, Q., Wang, Y., Zhu, Z., Zhao, H., Sun, J., Dong, L., Zhu, Y., Zhao, N., et al. (2017) · Xenobiotica · doi:10.1080/00498254.2016.1271960 · Cited by 25
“During the past two decades, an increasing incidence of IFIs has been observed attributing to the utilization of chemotherapeutic and immunosuppressive drugs, the treatment of broad-spectrum antibacterial, the presence of central venous lines and other devices traversing the epithelial barrier (Guery et al., 2009; Kri…”
BackgroundTowards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
Reinhold, I., Picardi, S., Liss, B., Seidel, D., Stemler, J., Koehler, P. A., Ruegamer, T., Sprute, R., & Cornely, O. A. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00409-8 · Cited by 25
Ylipalosaari, P., Ala-Kokko, T. I., Karhu, J., Koskela, M., Laurila, J., Ohtonen, P. P., & Syrjälä, H. (2012) · Critical Care · doi:10.1186/cc11307 · Cited by 30
Sinnollareddy, M., Roberts, M. S., Lipman, J., Lassig‐Smith, M., Starr, T., Robertson, T. A., Peake, S., & Roberts, J. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02461-15 · Cited by 24
Aslan, N., Yıldızdaş, D., Alabaz, D., Horoz, Ö. Ö., Yöntem, A., & Kocabaş, E. (2019) · Journal of Pediatric Intensive Care · doi:10.1055/s-0039-1695061 · Cited by 23
Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
Glöckner, A., & Karthaus, M. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01885.x · Cited by 25
The Enigma of the Major Repeat Sequence of Candida Albicans
Chibana, H., & Magee, P. T. (2009) · Future Microbiology · doi:10.2217/17460913.4.2.171 · Cited by 25
Posteraro, B., Ruggeri, A., Carolis, E. D., Torelli, R., Vella, A., Maio, F. D., Ricciardi, W., Posteraro, P., & Sanguinetti, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01581-13 · Cited by 23
Pratikaki, M. E., Platsouka, E. D., Sotiropoulou, C., Douka, E., Paramythiotou, E., Kaltsas, P., Kotanidou, A. N., Paniara, O., Roussos, C., & Routsi, C. (2011) · Mycoses · doi:10.1111/j.1439-0507.2009.01787.x · Cited by 27
Anidulafungin for the treatment of invasive candidiasis
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03448.x · Cited by 26
“Crude mortality rates remain substantial, ranging from 38% to 62% in Europe [5,12,20–22]; fatality rates of up to 75% have been reported in the USA [13].”
BackgroundBurden of serious fungal infections in Ukraine
Osmanov, A., & Denning, D. W. (2015) · Mycoses · doi:10.1111/myc.12409 · Cited by 20
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
“These possible treatment delays likely occurred because of the non-specific clinical presentation of candidemia, low sensitivity of blood cultures for candidemia detection, and the time needed to detect Candida in blood cultures [15, 27].”
BackgroundTimsit, J., Azoulay, É., Cornet, M., Gangneux, J., Jullien, V., Vesin, A., Schir, É., & Wolff, M. (2013) · Trials · doi:10.1186/1745-6215-14-399 · Cited by 22
“However, the performance of available diagnostic tools for diagnosing candidemia remains limited [11,12,18,19].”
BackgroundSelf-citationRecommendations for the diagnosis of candidemia in Latin America
Colombo, A. L., Cortés, J. A., Zurita, J., Guzmán-Blanco, M., Matute, T. A., Telles, F. D. Q., Santolaya, M. E., Tiraboschi, I. N., Echevarria, J. I., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.008 · Cited by 26
New nonculture-based methods for the diagnosis of invasive candidiasis
Billé, J. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e04df · Cited by 20
Kautzky, S., Staudinger, T., & Presterl, E. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0644-z · Cited by 17
Sinh, C. T., Loi, C. B., Minh, N. T., Lam, N. N., Quang, D. X., Đỗ, Q., Ánh, Đ. N., Hien, T. T. T., Su, H. X., & Le, T. (2021) · Mycopathologia · doi:10.1007/s11046-021-00569-7 · Cited by 17
Abdominal Aortic Aneurysm Associated with Systemic Fungal Infection in a German Shepherd Dog
Gershenson, R. T., Melidone, R., Sutherland‐Smith, J., & Rogers, C. L. (2010) · Journal of the American Animal Hospital Association · doi:10.5326/jaaha-ms-5630 · Cited by 17
“Reported risk factors in humans include broad-spectrum antibiotic use, mechanical ventilation, parenteral nutrition, hemodialysis, renal failure, prior surgery, neutropenia, chemotherapy, severe illness, age, and indwelling catheters (especially central venous catheters).(13) Although less commonly reported, veterinar…”
BackgroundPositive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery
Zappella, N., Desmard, M., Chochillon, C., Ribeiro‐Parenti, L., Houzé, S., Marmuse, J., & Montravers, P. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.05.024 · Cited by 16
van der Geest, P. J., Rijnders, B. J. A., Vonk, A. G., & Groeneveld, A. B. J. (2015) · Mycoses · doi:10.1111/myc.12450 · Cited by 17
Dąbrowski, M., Cieplak, M., Noworyta, K., Heim, M., Adamkiewicz, W., Kuhn, A., Sharma, P. S., & Kutner, W. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01407d · Cited by 16
Candidemias y candidiasis invasivas nosocomiales
Quindós, G. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.09.021 · Cited by 16
Candidal thrombophlebitis of central veins: case report and review
Caccese, R., Carfagna, P., Pistilli, N., Massetti, A. P., Falcone, M., & Venditti, M. (2012) · Medical Mycology · doi:10.3109/13693786.2011.604046 · Cited by 15
Self-citationDesign and use of Candida scores at the intensive care unit
Kratzer, C., Graninger, W., Lassnigg, A. M., & Presterl, E. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01953.x · Cited by 18
In vitro synergy of azole antifungals and methotrexate against Candida albicans
Yang, J., Gao, L., Yu, P., Kosgey, J. C., Jia, L., Fang, Y., Xiong, J., & Zhang, F. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116827 · Cited by 14
Limitation of (1→3)-β-D-glucan monitoring in major elective surgery involving cardiopulmonary bypass
Otto, G. P., Ludewig, K., Jacobsen, I. D., Schaarschmidt, B., Hube, B., & Bauer, M. W. (2013) · Critical Care · doi:10.1186/cc12718 · Cited by 14
Evaluation of the updated “Candida score” with Sepsis 3.0 criteria in critically ill patients
Li, D., Zhang, J., Han, W., Bai, G., Cheng, W., & Cui, N. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-995 · Cited by 13
“Numerous risk factors for ICI have been identified [5].”
BackgroundKarthaus, M., Rüping, M. J. G. T., Cornely, O. A., Steinbach, A., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Vehreschild, J. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01988.x · Cited by 14
Azoulay, É., Timsit, J., Lautrette, A., Legriel, S., Max, A., Ruckly, S., Misset, B., Cohen, Y., & Wolff, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177093 · Cited by 14
Self-citationvan der Geest, P. J., Hunfeld, N., Ladage, S. E., & Groeneveld, A. B. J. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1825-3 · Cited by 12
JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Candidiasis
(2013) · Medical Mycology Journal · doi:10.3314/mmj.54.147 · Cited by 12
Clinical Aspects of Invasive Candidiasis in the Surgical Patient
Sganga, G. (2009) · Drugs · doi:10.2165/11315600-000000000-00000 · Cited by 13
Self-citationDiagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
de Lacerda, J. F., & Meneses-Oliveira, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0023-3 · Cited by 12
“albicans has remained the prevalent species; however, non albicans species have been increasingly identified in the past decade [65].”
BackgroundInfluentialKhan, P. A., Fatima, N., Khan, H. M., & Malik, A. (2015) · Cited by 10
When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock
Allou, N., Allyn, J., & Montravers, P. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0204-x · Cited by 10
Impact of empirical treatment with antifungal agents on survival of patients with candidemia.
Poves‐Álvarez, R., Cano-Hernández, B., Muñoz-Moreno, M. F., Balbás-Alvarez, S., Román-García, P., Gómez-Sánchez, E., Martínez‐Rafael, B., Gómez‐Pesquera, E., Lorenzo‐López, M., Álvarez-Fuente, E., et al. (2019) · PubMed Central · Cited by 10
Haltmeier, T., Inaba, K., Effron, Z., Dollbaum, R., Shulman, I. A., Benjamin, E., Lam, L., & Δημητριάδης, Δ. (2015) · The American Surgeon · doi:10.1177/000313481508101031 · Cited by 9
SAR study of N′-(Salicylidene)heteroarenecarbohydrazides as promising antifungal agents
Sun, Y., Kim, S., Shin, S., Takemura, K., Matos, G. S., Lazzarini, C., Haranahalli, K., Zambito, J., Garg, A., Poeta, M. D., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117610 · Cited by 9
Special Issue: Novel Antifungal Drug Discovery
Poeta, M. D. (2016) · Journal of Fungi · doi:10.3390/jof2040033 · Cited by 9
Metadata
- Authors
- Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., Venditti, M., Zaragoza Crespo, R., & Kullberg, B. J.
- Affiliations
- Statens Serum Institut (DK)
- King's College Hospital (GB)
- Hôpital Saint-Louis (FR)
- University Hospitals of the Ruhr-University of Bochum (DE)
- University of Bonn (DE)
- University Health Network (CA)
- Università Cattolica del Sacro Cuore (IT)
- Sapienza University of Rome (IT)
- Radboud University Nijmegen (NL)
- Corresponding author
- Kullberg, Bart Jan
- ORCID
- Venue
- Intensive Care Medicine
- Published
- 2008-10-30
- Volume
- 35
- Issue
- 1
- Pages
- 55-62
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W2012383276
- Semantic Scholar
- cd5e9d6d2f04b85eba8f5f641d0d646b8f63bdb4
- Cited by
- 173
- References
- 58
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 11 · 2016: 15 · 2015: 17 · 2014: 18 · 2013: 14 · 2012: 11
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Intensive Care Medicine (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc)
- Hispana (submittedVersion, cc-by-nc)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Sanofi
- Gilead Sciences
- Fresenius Medical Care North America
- Astellas Pharma
- Novartis Pharma
- Bayer Vital
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- invasive candidiasis, candidemia, non-neutropenic patients, intensive care unit, Candida albicans, Candida glabrata, nosocomial fungal infections, risk factors, clinical scoring systems, blood culture, β-1,3-glucan, mannan, PCR detection, antifungal therapy, epidemiology
- MeSH terms
- Candidiasis, Cross Infection, Europe, Humans, Intensive Care Units, Turkey, Biomarkers, Prevalence, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.